Results 221 to 230 of about 411,716 (331)
SP1-IKBIP axis promotes the proliferation and invasion of glioma with Wnt/β-catenin associated epithelial-mesenchymal transition. [PDF]
Liu N +9 more
europepmc +1 more source
The many faces and functions of β‐catenin
T. Valenta, G. Hausmann, K. Basler
semanticscholar +1 more source
Marine silicon for biomedical sustainability
Schematic illustrating marine silicon for biomedical engineering. Abstract Despite momentous divergence from oceanic origin, human beings and marine organisms exhibit elemental homology through silicon utilization. Notably, silicon serves as a critical constituent in multiple biomedical processes.
Yahui Han +3 more
wiley +1 more source
Disrupting Akt-Wnt/β-catenin signaling suppresses glioblastoma stem cell growth and tumor progression in immunocompetent mice. [PDF]
Sarkar MM +6 more
europepmc +1 more source
Abstract Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer‐related mortality globally, continues to pose significant therapeutic challenges. Here, we developed an innovative nanosystem, Phl@PT, based on Pt‐TiO2 nanoparticles for the co‐delivery of Phlorezin, presenting a novel approach for HCC treatment through sonodynamic ...
Kairui Liu +13 more
wiley +1 more source
Plakoglobin transmits tension across VE-cadherin for vascular leak formation and leukocyte diapedesis. [PDF]
Uttekar N +8 more
europepmc +1 more source
ABSTRACT The complexity of breast cancer (BC) lung metastasis lies in the capacity of tumour cells to interact efficiently with distant organs to promote colonisation, a process that involves the sophisticated coordination of inherent cellular plasticity and the remodelling of the distant microenvironment.
Jian Lu +12 more
wiley +1 more source
Wnt/β-catenin signalling modulates the timing of cell fate decision making in the early mouse embryo. [PDF]
Lilao-Garzón J +6 more
europepmc +1 more source
Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu +5 more
wiley +1 more source

